GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2007

ChemGenex Recieves Patent Protection on Production of Leukemia Candidate

  • ChemGenex Pharmaceuticals’ patent related to the manufacture of its leukemia candidate received approval. The patent covers the semisynthetic production of homoharringtonine (Ceflatonin®) and its analogs and the use of these compounds in a treatment of leukemia. The patent provides ChemGenex and its partner, Stragen Pharma, with a proprietary position until 2019 in the U.S.

    Ceflatonin is a potent inducer of apoptosis in myeloid cells and inhibits angiogenesis. In Phase II studies, it demonstrated clinical activity in patients with chronic myeloid leukemia (CML), both as a single agent and in combination with other chemotherapeutic drugs, according to ChemGenex.

    The company is developing Ceflatonin for the treatment of CML, and pilot studies are underway in myelodysplastic syndrome (MDS) and in acute myeloid leukemia (AML).

    "In addition to the strong regulatory position obtained through patents and orphan drug status in major jurisdictions, the Ceflatonin clinical development program is progressing very well,” points out Greg Collier, Ph.D., CEO and managing director. “We now have 11 centers in the U.S.A. and Europe recruiting patients for our registration-directed trial of Ceflatonin in chronic myeloid leukemia patients with the T315I mutation who have failed Gleevec therapy."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »